Persistence of low-level DNMT3A mutations during remission in AML patients further supports the existence of pre-leukemic stem cells with CHDMs, which then represent a reservoir of pre-leukemic clones that can provoke a relapse [21]. Here, DNMT3A is linked to acute myeloid leukemia.